Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy

Sue C. Bodine(Regeneron (United States)), Esther Latres(Regeneron (United States)), Susanne Baumhueter, Venus Lai(Regeneron (United States)), Lorna Nuñez(Regeneron (United States)), Brian Clarke(Regeneron (United States)), William Poueymirou(Regeneron (United States)), Frank J. Panaro(Regeneron (United States)), Erqian Na(Regeneron (United States)), Kumar Dharmarajan(Regeneron (United States)), Zhen‐Qiang Pan(Icahn School of Medicine at Mount Sinai), David M. Valenzuela(Regeneron (United States)), Thomas M. DeChiara(Regeneron (United States)), Trevor N. Stitt(Regeneron (United States)), George D. Yancopoulos(Regeneron (United States)), David J. Glass(Regeneron (United States))
Science
November 23, 2001
Cited by 3,484Open Access
Full Text

Abstract

Skeletal muscle adapts to decreases in activity and load by undergoing atrophy. To identify candidate molecular mediators of muscle atrophy, we performed transcript profiling. Although many genes were up-regulated in a single rat model of atrophy, only a small subset was universal in all atrophy models. Two of these genes encode ubiquitin ligases: Muscle RING Finger 1 (MuRF1), and a gene we designate Muscle Atrophy F-box (MAFbx), the latter being a member of the SCF family of E3 ubiquitin ligases. Overexpression of MAFbx in myotubes produced atrophy, whereas mice deficient in either MAFbx or MuRF1 were found to be resistant to atrophy. These proteins are potential drug targets for the treatment of muscle atrophy.


Related Papers

No related papers found

Powered by citation graph analysis